NVCR
Novocure LtdNASDAQHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$2.08B
P/E Ratio
—
EPS
$-1.53
Beta
0.90
52W High
$20.06
52W Low
$9.82
50-Day MA
$13.59
200-Day MA
$12.88
Dividend Yield
—
Profit Margin
-25.70%
Forward P/E
909.09
PEG Ratio
-0.47
About Novocure Ltd
NovoCure Limited, an oncology company, is engaged in the development, manufacture and marketing of Optune for the treatment of a variety of solid tumors. The company is headquartered in Saint Helier, Jersey.
Fundamentals
| Revenue (TTM) | $674.41M |
| Gross Profit (TTM) | $508.84M |
| EBITDA | $-166.22M |
| Operating Margin | -38.70% |
| Return on Equity | -50.00% |
| Return on Assets | -11.10% |
| Revenue/Share (TTM) | $6.00 |
| Book Value | $2.85 |
| Price-to-Book | 6.29 |
| Price-to-Sales (TTM) | 3.08 |
| EV/Revenue | 2.791 |
| EV/EBITDA | -6.92 |
| Quarterly Earnings Growth (YoY) | -6.00% |
| Quarterly Revenue Growth (YoY) | 12.30% |
| Shares Outstanding | $115.82M |
| Float | $95.36M |
| % Insiders | 9.97% |
| % Institutions | 87.44% |
Historical Volatility
HV 10-Day
32.31%
HV 20-Day
99.78%
HV 30-Day
87.93%
HV 60-Day
74.88%
HV Rank
70.2%
Volatility is currently contracting
Analyst Ratings
Consensus ($26.29 target)
1
Strong Buy4
Buy2
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026